NHS Framework - Blood Disorders including Haemophilia A and B - July 2024
Details
- Buyer
- NHS England
- Value
- £1,168,000,000
- Topic
- Pharmaceutical products
- Published
- 19 February 2024
- Submission
- 21 March 2024
- Source
- uk:find_a_tender
Tender description
Project Title: NHS National Framework Agreement for the supply of products for the treatment of Blood Disorders including Haemophilia A and B - July 2024<br/><br/>Offer reference number: CM/PHS/22/5661<br/><br/>Period of framework: 1 July 2024 to 30 April 2027 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 14 months.<br/><br/>Published By: Medicines Procurement and Supply Chain – NHS Medicines Value & Access, NHS England Lot 1: CM/PHS/22/5661/01 Standard Half-life Recombinant Factor VIII Standard Half-life Recombinant Factor VIII Lot 2: CM/PHS/22/5661/02 Enhanced Half-life Recombinant Factor VIII CM/PHS/22/5661/02 Enhanced Half-life Recombinant Factor VIII Lot 3: CM/PHS/22/5661/03 Emicizumab CM/PHS/22/5661/03 Emicizumab Lot 4: CM/PHS/22/5661/04 eftrenonacog alfa (rFIX EHL) CM/PHS/22/5661/04 eftrenonacog alfa (rFIX EHL) Lot 5: CM/PHS/22/5661/05 albutrepenonacog alfa (rFIX EHL) CM/PHS/22/5661/05 albutrepenonacog alfa (rFIX EHL) Lot 6: CM/PHS/22/5661/06 nonacog beta pegol (rFIX EHL) CM/PHS/22/5661/06 nonacog beta pegol (rFIX EHL) Lot 7: CM/PHS/22/5661/07 rFIX - Standard Half Life CM/PHS/22/5661/07 rFIX - Standard Half Life Lot 8: CM/PHS/22/5661/08 Recombinant Factor VII CM/PHS/22/5661/08 Recombinant Factor VII Lot 9: CM/PHS/22/5661/09 Porcine Factor VIII - susoctocog alfa CM/PHS/22/5661/09 Porcine Factor VIII - susoctocog alfa Lot 10: CM/PHS/22/5661/10 Factor VIII Inhibitor Bypassing Fraction CM/PHS/22/5661/10 Factor VIII Inhibitor Bypassing Fraction Lot 11: CM/PHS/22/5661/11 Factor IX - High Purity Factor IX CM/PHS/22/5661/11 Factor IX - High Purity Factor IX Lot 12: CM/PHS/22/5661/12 Factor X CM/PHS/22/5661/12 Factor X Lot 13: CM/PHS/22/5661/13 Factor XIII - Plasma Derived CM/PHS/22/5661/13 Factor XIII - Plasma Derived Lot 14: CM/PHS/22/5661/14 Factor XIII - Recombinant CM/PHS/22/5661/14 Factor XIII - Recombinant Lot 15: CM/PHS/22/5661/15 Von willebrands factor / Factor VIII CM/PHS/22/5661/15 Von willebrands factor / Factor VIII Lot 16: CM/PHS/22/5661/16 Von willebrands factor - Plasma Derived CM/PHS/22/5661/16 Von willebrands factor - Plasma Derived Lot 17: CM/PHS/22/5661/17 Von willebrands factor - Recombinant CM/PHS/22/5661/17 Von willebrands factor - Recombinant Lot 18: CM/PHS/22/5661/18 Fibrinogen Concentrate CM/PHS/22/5661/18 Fibrinogen Concentrate Lot 19: CM/PHS/22/5661/19 Prothrombin Complex dried CM/PHS/22/5661/19 Prothrombin Complex dried Lot 20: CM/PHS/22/5661/20 Protein C Concentrate CM/PHS/22/5661/20 Protein C Concentrate Lot 21: CM/PHS/22/5661/21 Fresh Frozen Plasma (all blood groups) CM/PHS/22/5561/21 Fresh Frozen Plasma (all blood groups) Lot 22: CM/PHS/22/5661/22 Freeze Dried Plasma CM/PHS/22/5661/22 Freeze Dried Plasma Lot 23: CM/PHS/22/5661/23 Caplacizumab CM/PHS/22/5661/23 Caplacizumab Lot 1: CM/PHS/22/5661/01 Standard Half-life Recombinant Factor VIII Standard Half-life Recombinant Factor VIII Lot 2: CM/PHS/22/5661/02 Enhanced Half-life Recombinant Factor VIII CM/PHS/22/5661/02 Enhanced Half-life Recombinant Factor VIII Lot 3: CM/PHS/22/5661/03 Emicizumab CM/PHS/22/5661/03 Emicizumab Lot 4: CM/PHS/22/5661/04 eftrenonacog alfa (rFIX EHL) CM/PHS/22/5661/04 eftrenonacog alfa (rFIX EHL) Lot 5: CM/PHS/22/5661/05 albutrepenonacog alfa (rFIX EHL) CM/PHS/22/5661/05 albutrepenonacog alfa (rFIX EHL) Lot 6: CM/PHS/22/5661/06 nonacog beta pegol (rFIX EHL) CM/PHS/22/5661/06 nonacog beta pegol (rFIX EHL) Lot 7: CM/PHS/22/5661/07 rFIX - Standard Half Life CM/PHS/22/5661/07 rFIX - Standard Half Life Lot 8: CM/PHS/22/5661/08 Recombinant Factor VII CM/PHS/22/5661/08 Recombinant Factor VII Lot 9: CM/PHS/22/5661/09 Porcine Factor VIII - susoctocog alfa CM/PHS/22/5661/09 Porcine Factor VIII - susoctocog alfa Lot 10: CM/PHS/22/5661/10 Factor VIII Inhibitor Bypassing Fraction CM/PHS/22/5661/10 Factor VIII Inhibitor Bypassing Fraction Lot 11: CM/PHS/22/5661/11 Factor IX - High Purity Factor IX CM/PHS/22/5661/11 Factor IX - High Purity Factor IX Lot 12: CM/PHS/22/5661/12 Factor X CM/PHS/22/5661/12 Factor X Lot 13: CM/PHS/22/5661/13 Factor XIII - Plasma Derived CM/PHS/22/5661/13 Factor XIII - Plasma Derived Lot 14: CM/PHS/22/5661/14 Factor XIII - Recombinant CM/PHS/22/5661/14 Factor XIII - Recombinant Lot 15: CM/PHS/22/5661/15 Von willebrands factor / Factor VIII CM/PHS/22/5661/15 Von willebrands factor / Factor VIII Lot 16: CM/PHS/22/5661/16 Von willebrands factor - Plasma Derived CM/PHS/22/5661/16 Von willebrands factor - Plasma Derived Lot 17: CM/PHS/22/5661/17 Von willebrands factor - Recombinant CM/PHS/22/5661/17 Von willebrands factor - Recombinant Lot 18: CM/PHS/22/5661/18 Fibrinogen Concentrate CM/PHS/22/5661/18 Fibrinogen Concentrate Lot 19: CM/PHS/22/5661/19 Prothrombin Complex dried CM/PHS/22/5661/19 Prothrombin Complex dried Lot 20: CM/PHS/22/5661/20 Protein C Concentrate CM/PHS/22/5661/20 Protein C Concentrate Lot 21: CM/PHS/22/5661/21 Fresh Frozen Plasma (all blood groups) CM/PHS/22/5561/21 Fresh Frozen Plasma (all blood groups) Lot 22: CM/PHS/22/5661/22 Freeze Dried Plasma CM/PHS/22/5661/22 Freeze Dried Plasma Lot 23: CM/PHS/22/5661/23 Caplacizumab CM/PHS/22/5661/23 Caplacizumab
Timeline
- Completed: Tender published19 February 2024Current notice
- Completed: Submission date21 March 2024
About the buyer
NHS England runs the NHS in England, and buys as a central healthcare organisation with its own team of procurement professionals. Much of this procurement flows through framework agreements and the Crown Commercial Service. Seven regional teams support the commissioning of healthcare services across the country. The central commercial function that develops procurement strategy for the whole NHS sits here.
Clinical services are commissioned directly or through the Provider Selection Regime.
Over the past 5 years, most of NHS England's contract awards have been in education and training, health and social work, and IT services.
Decision makers
Connect with the people behind this procurement.
| Contact name | Job title | Phone number | Work email |
|---|---|---|---|
| Head of Procurement | +44 •••• •••••• | ••••••••@nhs-england.gov | |
| Commercial Director | +44 •••• •••••• | ••••••••@nhs-england.gov | |
| Procurement Manager | +44 •••• •••••• | ••••••••@nhs-england.gov | |
| Category Lead | +44 •••• •••••• | ••••••••@nhs-england.gov | |
| Senior Buyer | +44 •••• •••••• | ••••••••@nhs-england.gov | |
| Contracts Manager | +44 •••• •••••• | ••••••••@nhs-england.gov |
15 similar open tenders
See more open tenders related to Pharmaceutical products.
- Open tender
Injection Equipment Paraphernalia
- Open tender
NP93827 Seasonal Influenza Vaccine
- Open tender
NP93827 Seasonal Influenza Vaccine
- Open tender
Hepatitis C Medicines
- Open tender
NHS National Framework for Lenvatinib
- Open tender
IMP Manufacture, Labelling and Packaging DPS
Related topics
Topics related to NHS Framework - Blood Disorders including Haemophilia A and B - July 2024, ranked by notice volume.
- 45,396£7.9tn
Related buyers
Buyers similar to NHS England.
- 511£247.2m
- 437£12.4bn
- 407£110.0m
- 393£653.2m
- 329£25.1bn
- 320£1.3bn
- 297£1.6bn
- 278£3.0bn
- 154£114.1m
- 151£1.0bn
Finding public sector work shouldn't be hard
Make your next tender search effortless with Stotles. Set up alerts, find decision maker contacts and never miss a good-fit opportunity again.